Eledon Pharmaceuticals, Inc.

EDGAR

Market value

$199.32M

84,459,713 shares as of 2026-11-10, at $2.36 a share (ELDN, IEX close on 2026-11-12) Primary-source evidence

104 filing records in this dataset, filed from 2014-08-11 to 2026-11-12. Reported financial figures are available; chart coverage varies by period.

Watchlist

Holdings and insider activity

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, over the last 12 months.

Window: transactions dated on or after 2025-11-22.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

  • 2035-01-10 Robinson James A. Jr. A 30,870 0
  • 2026-07-31 Perrin Steven A 152,353 0
  • 2026-07-31 Perrin Steven F 72,138 3.38
  • 2026-07-31 Gros David-Alexandre C A 354,454 0
  • 2026-07-31 Gros David-Alexandre C F 194,791 3.38

5% holders (Schedule 13D and 13G)

  • BIOTECHNOLOGY VALUE FUND L P 7.0% SCHEDULE 13G/A 09/30/2026
  • BVF I GP LLC 7.0% SCHEDULE 13G/A 09/30/2026
  • BIOTECHNOLOGY VALUE FUND II LP 2.6% SCHEDULE 13G/A 09/30/2026

Institutional holders (Form 13F)

  • BlackRock, Inc. 6,641,297 SH
  • BVF INC/IL 6,293,282 SH
  • Defilade Capital Management, L.P. 3,525,338 SH
  • VANGUARD CAPITAL MANAGEMENT LLC 3,417,223 SH
  • GOLDMAN SACHS GROUP INC 2,561,285 SH

Trades by members of Congress

See all insider transactions

Latest fiscal year

Revenue

0 USD

2016 · USD

Exact inputs and evidence

Operating cash flow

-4.92 million USD

2016 · USD

Exact inputs and evidence
  • Operating Cash Flow: -4923000 USD Source

Free cash flow

-4.93 million USD

2016 · USD

Exact inputs and evidence
  • Operating Cash Flow: -4923000 USD Source
  • Capital Expenditure: 9000 USD Source
Cash and cash equivalents
6.88 million USD Source
Exact value

6882000 USD

Long-term debt including current maturities
Not available
Shares outstanding
81.4 million shares Source
Exact value

81442402 shares

Reported share-count change

36.01% · 21.6 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence
  • 59881775 shares · 2025-09-30· Source
  • 81442402 shares · 2026-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-85 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence
  • Net income: -45617000 USD · 2025-01-01 – 2025-12-31 Source
  • Net income: -35170000 USD · 2025-01-01 – 2025-09-30 Source
  • Net income: -39025000 USD · 2026-01-01 – 2026-03-31 Source
  • Net income: -31630000 USD · 2026-04-01 – 2026-06-30 Source
  • Net income: -3933000 USD · 2026-07-01 – 2026-09-30 Source

Operating cash flow

-78.4 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence
  • Operating cash flow: -62341000 USD · 2025-01-01 – 2025-12-31 Source
  • Operating cash flow: -48250000 USD · 2025-01-01 – 2025-09-30 Source
  • Operating cash flow: -22612000 USD · 2026-01-01 – 2026-03-31 Source
  • Operating cash flow: -45289000 USD · 2026-01-01 – 2026-06-30 Source
  • Operating cash flow: -22612000 USD · 2026-01-01 – 2026-03-31 Source
  • Operating cash flow: -64269000 USD · 2026-01-01 – 2026-09-30 Source
  • Operating cash flow: -45289000 USD · 2026-01-01 – 2026-06-30 Source

Company performance

Up to ten complete financial years · consolidated figures

Latest filing vintage with reviewed corrections applied; these values remain separate from issuer-reported figures. Annual charts exclude incomplete years.

Latest filing recorded: 2026-11-12.

Financial data available through: 2025-12-31.

Coverage by financial measure
  • Revenue: 2 of 11 periods available· newest 2016-12-31
  • Operating income: 9 of 11 periods available· newest 2023-12-31
  • Net income: 11 of 11 periods available· newest 2025-12-31
  • Operating cash flow: 11 of 11 periods available· newest 2025-12-31
  • Capital expenditure: 2 of 11 periods available· newest 2016-12-31
  • Total assets: 11 of 11 periods available· newest 2025-12-31
  • Total liabilities: 11 of 11 periods available· newest 2025-12-31
  • Current assets: 11 of 11 periods available· newest 2025-12-31
  • Current liabilities: 10 of 11 periods available· newest 2025-12-31
  • Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
  • long term debt: No compatible figures in this window
  • Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

  • Net income

    −USD 9.43 million

    Prior period

    −USD 36.18 million

    –

    Current period

    −USD 45.62 million

    –

    Exact inputs and evidence

    -45617000 − -36184000 = -9433000 USD

    -36184000 USD · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    -45617000 USD · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Operating cash flow

    −USD 15.07 million

    Prior period

    −USD 47.27 million

    –

    Current period

    −USD 62.34 million

    –

    Exact inputs and evidence

    -62341000 − -47271000 = -15070000 USD

    -47271000 USD · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    -62341000 USD · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2016 2016-01-01 – 2016-12-31

  • Revenue USD 0
  • Operating costs Derived USD 5.13 million
  • Operating income −USD 5.13 million
  • Tax, interest and other Derived USD 527,000
  • Net income −USD 5.66 million

Cash

  • Operating cash flow −USD 4.92 million
  • Capital expenditure USD 9,000
  • Free cash flow Derived −USD 4.93 million

Share of revenue by period

  • Net income
  • Tax, interest and other
  • Operating costs
  • 2016 Not shown: operating income or net income is not reported.
Values and sources
Revenue breakdown by annual reporting period
PeriodRevenueOperating costsOperating incomeTax, interest and otherNet incomeFree cash flowSource
2016 2016-01-01 – 2016-12-310 5128000 Derived -5128000 527000 Derived -5655000 -4932000 Derived
Source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2016
Revenue historyRevenue reported for each complete financial period. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.1.10.80.50.30.020152016
Values and sources
Revenue values and source evidence
PeriodSeriesValue(USD)Source evidence
2015Revenue0
2016Revenue0

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.
Values and sources
Revenue growth values and source evidence
PeriodSeriesValueSource evidence
2015Year over yearNo prior comparable period
2016Year over yearNo prior comparable period

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.
  • Operating margin
  • Net margin
  • Free cash flow margin
Values and sources
Profit margins values and source evidence
PeriodSeriesValueSource evidence
2015Operating marginNot reported
2016Operating marginNot reported
2015Net marginNot reported
2016Net marginNot reported
2015Free cash flow marginNot reported
2016Free cash flow marginNot reported

Operating cash flow

Cash generated by the company’s normal business operations.

USD -4.9M 2016
Operating cash flow historyCash generated by the company’s normal business operations. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.393.8K-1.0M-2.5M-3.9M-5.3M20152016
Values and sources
Operating cash flow values and source evidence
PeriodSeriesValue(USD)Source evidence
2015Operating cash flowNot reportedNo source recorded
2016Operating cash flow-4923000

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -4.9M 2016
Free cash flow historyOperating cash flow minus capital expenditure for the same period and unit. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.394.6K-1.0M-2.5M-3.9M-5.3M20152016
Values and sources
Free cash flow values and source evidence
PeriodSeriesValue(USD)Source evidence
2015Free cash flowUnavailableNo source recorded
2016Free cash flow-4932000

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

325.9% 2016
Liabilities to assets historyTotal liabilities as a share of total assets. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.352%264%176%88%0%20152016
Values and sources
Liabilities to assets values and source evidence
PeriodSeriesValueSource evidence
2015Liabilities / assets9.2%
2016Liabilities / assets325.9%

Current assets to current liabilities

Current assets divided by current liabilities.

0.3× 2016
Current assets to current liabilities historyCurrent assets divided by current liabilities. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.11.77×8.83×5.89×2.94×0.00×20152016
Values and sources
Current assets to current liabilities values and source evidence
PeriodSeriesValueSource evidence
2015Current assets / current liabilities10.9×
2016Current assets / current liabilities0.3×

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
PeriodNet incomeOperating cash flowCapital expenditureFree cash flow
2016 2016-01-01 – 2016-12-31
−USD 5.66 million
Exact value

Exact value: -5655000 USD

2016-01-01 – 2016-12-31: -5655000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 4.92 million
Exact value

Exact value: -4923000 USD

2016-01-01 – 2016-12-31: -4923000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 9,000
Exact value

Exact value: 9000 USD

2016-01-01 – 2016-12-31: 9000 USD Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 4.93 million
Calculation and evidence

-4923000 − 9000 USD

Exact free cash flow: -4932000 USD

Share or cite

The citation records this snapshot. The page link may show a newer release later.

2017 2017-01-01 – 2017-12-31
−USD 13.12 million
Exact value

Exact value: -13116000 USD

2017-01-01 – 2017-12-31: -13116000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 14.94 million
Exact value

Exact value: -14941000 USD

2017-01-01 – 2017-12-31: -14941000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

2018 2018-01-01 – 2018-12-31
−USD 14.07 million
Exact value

Exact value: -14065000 USD

2018-01-01 – 2018-12-31: -14065000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 11.89 million
Exact value

Exact value: -11893000 USD

2018-01-01 – 2018-12-31: -11893000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

2019 2019-01-01 – 2019-12-31
−USD 16.01 million
Exact value

Exact value: -16011000 USD

2019-01-01 – 2019-12-31: -16011000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 13.86 million
Exact value

Exact value: -13857000 USD

2019-01-01 – 2019-12-31: -13857000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

2020 2020-01-01 – 2020-12-31
−USD 22.81 million
Exact value

Exact value: -22811000 USD

2020-01-01 – 2020-12-31: -22811000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 15.21 million
Exact value

Exact value: -15212000 USD

2020-01-01 – 2020-12-31: -15212000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

2021 2021-01-01 – 2021-12-31
−USD 34.51 million
Exact value

Exact value: -34506000 USD

2021-01-01 – 2021-12-31: -34506000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 28.91 million
Exact value

Exact value: -28913000 USD

2021-01-01 – 2021-12-31: -28913000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

2022 2022-01-01 – 2022-12-31
−USD 87.97 million
Exact value

Exact value: -87966000 USD

2022-01-01 – 2022-12-31: -87966000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 28.42 million
Exact value

Exact value: -28424000 USD

2022-01-01 – 2022-12-31: -28424000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

2023 2023-01-01 – 2023-12-31
−USD 116.54 million
Exact value

Exact value: -116537000 USD

2023-01-01 – 2023-12-31: -116537000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 39.53 million
Exact value

Exact value: -39527000 USD

2023-01-01 – 2023-12-31: -39527000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

2024 2024-01-01 – 2024-12-31
−USD 36.18 million
Exact value

Exact value: -36184000 USD

2024-01-01 – 2024-12-31: -36184000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 47.27 million
Exact value

Exact value: -47271000 USD

2024-01-01 – 2024-12-31: -47271000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

2025 2025-01-01 – 2025-12-31
−USD 45.62 million
Exact value

Exact value: -45617000 USD

2025-01-01 – 2025-12-31: -45617000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 62.34 million
Exact value

Exact value: -62341000 USD

2025-01-01 – 2025-12-31: -62341000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

104 filings · 2,187 latest values · 2,187 originally reported values

Dataset published . Source filing dates and reporting periods are shown separately.

Identifiers: 0001404281, 1404281, ELDN, NVUS, TKAI, edgar:1404281

Also known as ELEDON PHARMACEUTICALS, INC., Eledon Pharmaceuticals, Inc., Novus Therapeutics, Inc., TOKAI PHARMACEUTICALS INC, Tokai Pharmaceuticals Inc